Autolus Therapeutics
Price & Volume
Stats
See more52W Range | $2.69-$7.45 |
Market Cap | $782.3M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $10M |
Revenue Growth (YoY) | 681% |
Gross Profit (12 Mos) | -$130.8M |
Diluted EPS | -$1.22 |
News
See moreYahoo Finance • 10 months ago
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
Yahoo Finance • 12 months ago
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
Yahoo Finance • last year
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
Yahoo Finance • last year
Autolus Therapeutics announces participation in upcoming conferences
About
CEO | Dr. Christian Martin Itin Ph.D. |
CFO | Mr. Robert F. Dolski |
Address | The Mediaworks, London, United Kingdom, W12 7FP |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 463 |
